QIAGEN (QGEN)
(Delayed Data from NYSE)
$45.51 USD
+1.06 (2.38%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $45.53 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Brokerage Reports
QIAGEN N.V. [QGEN]
Reports for Purchase
Showing records 181 - 200 ( 239 total )
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q15 Preview - Lowering Forecasts Slightly - Expecting Sales to Edge Higher With In-line EPS - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Final 4Q14 Recap - Lower Estimates Offset By An Interesting Two-Quarter System Sales Growth Trend - FCF Ok - Reaffirm NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Pre-Call Summary - 4Q14 Results Mixed - System Sales Strong, But Offset by Weaker HPV - EPS Ok - FCF Stable - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 26
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Expecting 4Q14 Results In Line with Reaffirmation - Enzymatics Tuck-In, Quantiferon Competition - FCF Top of Mind - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q14 Sales & EPS In line - Profiling Tests & Instruments Stand Out - Weaker HPV Offsets Strength - FCF Improving Nicely - PT to $21 - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q14 Preview - Expecting In-line Results - More Optimistic on EU Post Recent Earnings
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q14 Results Meet Street Expectations - Better Profiling Offset by Challenging Academic & Pharma
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 28
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q14 Preview - Expecting Ok Top-line With EPS Upside from Mix & Opex Leverage
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Tweaking EPS Estimates Above Consensus After Model Rebuild
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q14 Pre-Call Summary - Financials Ok - Guidance Reaffirmed - Another Buyback Announced
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q14 Pre-Call Summary - Financials Ok - Guidance Reaffirmed
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z